BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT
Delisted
BMY.RT was delisted on the 31st of December, 2020.
544 hedge funds and large institutions have $338M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 81 increasing their positions, 199 reducing their positions, and 102 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding in top 10
Funds holding in top 10: →
59% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 199
71% less capital invested
Capital invested by funds: $1.18B → $338M (-$844M)
Holders
544
Holding in Top 10
5
Calls
$558K
Puts
$86K
Top Buyers
| 1 | +$21.4M | |
| 2 | +$8.2M | |
| 3 | +$6.9M | |
| 4 |
SCM
Stonehill Capital Management
New York
|
+$4.6M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$3.92M |
Top Sellers
| 1 | -$51M | |
| 2 | -$17.9M | |
| 3 | -$16.8M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.6M |
| 5 |
BM
Bridger Management
New York
|
-$9.96M |